ECbiomarker

Pubmed	Biomarker	P-value	Description
34109467	HE4	p<0.001	Serum HE4 levels was significantly associated with older age
16980945	AIB1		High plasma GDF-15 was significantly associated with older age
36715558	HE4	p=0.02	Older age (odds ratio [OR] 0.96, 95% CI 0.93-0.99, p = 0.02), baseline serum HE4 (OR 0.97, 95% CI 0.96-0.99, p = 0.001) and endometrial cancer histology (OR 0.22, 95% CI 0.72-0.68, p = 0.009) were associated with a lower likelihood of progestin treatment response.
30134343	PD-L1	p=0.013	There was a significant difference between the staining scores of PD-L1 in tumor cells and age
30134343	PD-L2	p=0.043	a difference was found between the staining scores of PD-L2 in immune cells and age
29898448	ProGRP(Gastrin-releasing peptide)	p=0.006	Age was positively correlated with ProGRP levels（r=0.322）
28965628	cyclin D1	p=0.0001	High score cyclin D1 immunohistochemical staining has been significantly linked with patient age
26763250	POLE exonuclease domain mutations (EDM)	p<0.001	The median age of POLE mutated patients (58 years) was statistically different from patients with POLE wild-type tumours (66 years).
26763250	POLE exonuclease domain mutations (EDM)		A logistic regression model with variable selection to show that the odds of having a POLE mutation were decreased with age (OR (odds ratio) 0.94 (95% CI 0.9-0.99) per year), BMI (OR 0.92 (95% CI 0.84-0.98) per unit increase) and advanced Stage (OR 0.04 (95% CI 0-0.39) relative to Stage I).
21616994	GDF-15	p<0.001	As the age of the patient decreased, the tumour was found to show less oestrogen receptor expression
17130035	oestrogen receptor	p=0.003	AIB1 expression correlates with older age

34109467

HE4

p<0.001

Serum HE4 levels was significantly associated with older age

16980945

AIB1

High plasma GDF-15 was significantly associated with older age

36715558

HE4

p=0.02

Older age (odds ratio [OR] 0.96, 95% CI 0.93-0.99, p = 0.02), baseline serum HE4 (OR 0.97, 95% CI 0.96-0.99, p = 0.001) and endometrial cancer histology (OR 0.22, 95% CI 0.72-0.68, p = 0.009) were associated with a lower likelihood of progestin treatment response.

30134343

PD-L1

p=0.013

There was a significant difference between the staining scores of PD-L1 in tumor cells and age

30134343

PD-L2

p=0.043

a difference was found between the staining scores of PD-L2 in immune cells and age

29898448

ProGRP(Gastrin-releasing peptide)

p=0.006

Age was positively correlated with ProGRP levels（r=0.322）

28965628

cyclin D1

p=0.0001

High score cyclin D1 immunohistochemical staining has been significantly linked with patient age

26763250

POLE exonuclease domain mutations (EDM)

p<0.001

The median age of POLE mutated patients (58 years) was statistically different from patients with POLE wild-type tumours (66 years).

26763250

POLE exonuclease domain mutations (EDM)

A logistic regression model with variable selection to show that the odds of having a POLE mutation were decreased with age (OR (odds ratio) 0.94 (95% CI 0.9-0.99) per year), BMI (OR 0.92 (95% CI 0.84-0.98) per unit increase) and advanced Stage (OR 0.04 (95% CI 0-0.39) relative to Stage I).

21616994

GDF-15

p<0.001

As the age of the patient decreased, the tumour was found to show less oestrogen receptor expression

17130035

oestrogen receptor

p=0.003

AIB1 expression correlates with older age